Jazz Pharmaceuticals PLC detailed positive Phase III data on a next-generation narcolepsy drug that could extend the company's solid position in the space at the World Sleep meeting on 26 September. The company is hoping to file a new drug application for the product, JZP-258, by the end of the year, after meeting with the US Food and Drug Administration.
JZP-258 is positioned as a safer version of Jazz's blockbuster Xyrem (sodium oxybate). It is being developed for the treatment...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
